Advertisement
Document › Details
Biognosys AG. (5/19/21). "Press Release: Biognosys Announces the Appointment of Kristina Beeler as Chief Business Officer". Schlieren.
Organisation | Biognosys AG | |
Group | Bruker (Group) | |
Organisation 2 | Nextech Invest Ltd. (CH) | |
Group | Nextech (Group) | |
Product | proteomic technology | |
Product 2 | mass spectrometry (MS) | |
Person | Beeler, Kristina (Biognosys 202105– CBO before Head of Business Development joined 2017 before Nextech Invest) | |
Person 2 | Rinner, Oliver (Biognosys 202109 CEO + Co-Founder) | |
As new CBO, Kristina Beeler will continue to further potentiate the value of proteomics by collaborating with global partners
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the appointment of Kristina Beeler as Chief Business Officer. In this role, Kristina will serve as a member of Biognosys’ executive management and will be responsible for leading the company’s global commercial and business development activities for its contract research business.
Kristina joined Biognosys in 2017 and held positions of increasing responsibility in Business Development focused on Biognosys’ next-generation proteomics services. Before joining Biognosys, Kristina gained experience in biotech evaluation and investing in her function as Principal at Nextech Invest, a Swiss-based venture capital firm focused on identifying transformative cancer medicines and investing in emerging biotechnology companies.
Kristina has a strong scientific background in immunology and oncology, which she obtained during her Master Studies at the University of Oxford and her Doctoral Studies at the University of Zurich.
As Chief Business Officer, Kristina will be leading Biognosys’ commercial and business development activities focused on increasing the impact next-generation proteomics has on drug discovery and development. Key focus areas will be the commercial expansion of Biognosys in the US and strengthening the commercial activities to meet the growing demand for proteomics in large-scale clinical studies.
Kristina Beeler, PhD, CBO commented: “I am thrilled about the impact Biognosys’ leading proteomics technology has on revolutionizing drug development. I am looking forward to working with our global partners to further potentiate the value of proteomics.”
Oliver Rinner, PhD, CEO stated: “I am delighted to welcome Kristina to our executive management team. With her deep knowledge of biotechnology and understanding of our customers’ research goals, she is ideally suited to providing them with access to the proteome to advance their drug discovery and clinical research.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
Media Contact Biognosys
Kristina Beeler, PhD
Chief Business Officer
Phone +41 (0) 44 738 20 47
Mobile +41 (0) 79 937 75 68
kristina.beeler@biognosys.com
Record changed: 2023-06-05 |
Advertisement
More documents for Bruker (Group)
- [1] NanoString Technologies, Inc.. (4/17/24). "Press Release: NanoString Technologies to Be Acquired by Bruker Corporation. Bruker Wins Competitive Auction". Seattle, WA....
- [2] Biognosys AG. (4/4/24). "Press Release: Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research". Zürich & Fremont, CA....
- [3] Bruker Corporation. (1/25/24). "Press Release: Bruker Announces Agreement to Acquire Chemspeed". Basel....
- [4] Bruker Corporation. (1/23/24). "Press Release: Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts". Zürich & Newton, MA....
- [5] Bruker Corporation. (1/3/24). "Press Release: Bruker Acquires Electron Microscopy Company Nion". Billerica, MA....
- [6] Bruker Corporation. (12/26/23). "Form 8-K. Current Report [Acquisition of Elitech Group by Bruker for €870m from PAI Partners] CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest ev...
- [7] Bruker Corporation. (10/4/23). "Press Release: Bruker Announces Majority Investment in MIRO Analytical AG, an Innovator in Compact, Highest-Precision QCL-Based Multi-Gas Analyzers (MGA)". Zürich....
- [8] Bruker Corporation. (10/3/23). "Press Release: Bruker Completes Acquisition of PhenomeX". Billerica, MA....
- [9] Bruker Corporation. (9/18/23). "Press Release: Bruker Introduces Novel 4D-Proteomics timsTOF Capabilities". Busan....
- [10] Bruker Corporation. (8/17/23). "Press Release: Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction". Billerica, MA & Emeryville, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top